These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

68 related articles for article (PubMed ID: 1924667)

  • 21. Prediction of response to haloperidol in schizophrenia: neuroendocrine, neuromorphological and clinical variables.
    Mauri MC; Vita A; Giobbio GM; Ferrara A; Dieci M; Bitetto A; Altamura AC
    Int Clin Psychopharmacol; 1994; 9(1):3-7. PubMed ID: 8195579
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Correlations between akathisia and residual psychopathology: a by-product of neuroleptic-induced dysphoria.
    Newcomer JW; Miller LS; Faustman WO; Wetzel MW; Vogler GP; Csernansky JG
    Br J Psychiatry; 1994 Jun; 164(6):834-8. PubMed ID: 7952993
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Total and free plasma neuroleptic levels in schizophrenic patients.
    Tang SW; Glaister J; Davidson L; Toth R; Jeffries JJ; Seeman P
    Psychiatry Res; 1984 Dec; 13(4):285-93. PubMed ID: 6596586
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Early response to haloperidol treatment in chronic schizophrenia.
    Stern RG; Kahn RS; Harvey PD; Amin F; Apter SH; Hirschowitz J
    Schizophr Res; 1993 Aug; 10(2):165-71. PubMed ID: 8398949
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Predicting neuroleptic response from a combination of multilevel variables in acute schizophrenic patients.
    Bartkó G; Frecska E; Horváth S; Zádor G; Arató M
    Acta Psychiatr Scand; 1990 Dec; 82(6):408-12. PubMed ID: 1981296
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Response to antipsychotic medication: the doctor's and the consumer's view.
    Van Putten T; May PR; Marder SR
    Am J Psychiatry; 1984 Jan; 141(1):16-9. PubMed ID: 6691455
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Butaclamol hydrochloride in newly admitted schizophrenics.
    Hollister LE; Davis KL; Berger PA
    Psychopharmacol Commun; 1975; 1(5):493-500. PubMed ID: 778939
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Haloperidol for acute schizophrenic patients. An evaluation of three oral regimens.
    Donlon PT; Hopkin JT; Tupin JP; Wicks JJ; Wahba M; Meadow A
    Arch Gen Psychiatry; 1980 Jun; 37(6):691-5. PubMed ID: 7387340
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Clinical implications of determination of plasma haloperidol levels.
    Santos JL; Cabranes JA; Almoguera I; Ramos JA; Vazquez C; Angeles F
    Acta Psychiatr Scand; 1989 Apr; 79(4):348-54. PubMed ID: 2735205
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Familial schizophrenia and treatment response.
    Silverman JM; Mohs RC; Davidson M; Losonczy MF; Keefe RS; Breitner JC; Sorokin JE; Davis KL
    Am J Psychiatry; 1987 Oct; 144(10):1271-6. PubMed ID: 3661762
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A comparison of chlorprothixene and haloperidol in acute schizophrenia.
    Marjerrison G; Bowman R; Keogh RP
    Can Psychiatr Assoc J; 1971 Dec; 16(6):533-6. PubMed ID: 4947173
    [No Abstract]   [Full Text] [Related]  

  • 32. Subjective response to neuroleptics and outcome in schizophrenia: a re-examination comparing two measures.
    Hogan TP; Awad AG
    Psychol Med; 1992 May; 22(2):347-52. PubMed ID: 1615101
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Blink rate response to haloperidol as possible predictor of therapeutic outcome.
    Bartkó G; Herczeg I; Zádor G
    Biol Psychiatry; 1990 Jan; 27(1):113-5. PubMed ID: 2297547
    [No Abstract]   [Full Text] [Related]  

  • 34. Early subjective response and prediction of outcome to neuroleptic drug therapy in schizophrenia.
    Hogan TP; Awad AG; Eastwood MR
    Can J Psychiatry; 1985 Jun; 30(4):246-8. PubMed ID: 2861887
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Orthostatic challenge during neuroleptic test dose: a possible predictor of short-term outcome.
    Volz HP; Mackert A; Diefenbacher A; Friedrich A; Gaebel W; Müller H; Stock G; Möller HJ
    Neuropsychobiology; 1994; 30(2-3):94-100. PubMed ID: 7800170
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Level of haloperidol in plasma is related to electroencephalographic findings in patients who improve.
    Czobor P; Volavka J
    Psychiatry Res; 1992 May; 42(2):129-44. PubMed ID: 1631250
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Psychopharmacological study of schizophrenia--some ways out of an impasse. A case study with haloperidol.
    Singh MM
    Int Pharmacopsychiatry; 1973; 8(1):80-98. PubMed ID: 4595193
    [No Abstract]   [Full Text] [Related]  

  • 38. Urinary retention in the course of neuroleptic therapy with haloperidol.
    Ulmar G; Schunck H; Kober C
    Pharmacopsychiatry; 1988 Jul; 21(4):208-9. PubMed ID: 3205888
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Residual neuroleptic-induced parkinsonian symptoms in schizophrenia. A naturalistic study with orphenadrine.
    Altamura AC; Mauri MC; De Novellis F; Percudani M; Vampini V
    Pharmacopsychiatry; 1989 Nov; 22(6):246-9. PubMed ID: 2616635
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Time course and clinical predictors of treatment response in schizophrenia.
    Harvey PD; Davidson M; Powchik P; Schmeidler J; McQueeney R; Kaminsky R; Davis KL
    Schizophr Res; 1991 Sep; 5(2):161-6. PubMed ID: 1931808
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.